Table of Contents
BPC 157 - All you need to know
What is BPC 157?
BPC-157, or Body Protection Compound 157 is a synthetic peptide consisting of 15 amino acids. It is derived from a peptide sequence which is related to the protective compounds studied in gastric tissue.
BPC-157 is of particular scientific interest for its role in tissue repair, inflammatory signalling, blood vessel regulation and gastrointestinal protection. Its effects have been studied in preclinical studies in models of tendons, ligaments, muscles, skin, bone and the digestive tract.
Effects on fibroblast activity, collagen organisation, angiogenic signalling and nitric-oxide pathways have been reported in animal and laboratory studies . But most of the evidence that has been published comes from rodents or laboratory models and the findings still need to be confirmed in large, robust clinical trials in human beings.
This product is supplied for laboratory research purposes only and is supplied as lyophilised powder containing 5mg BPC-157. It is not licenced as a drug and is not intended for human consumption.
How much BPC 157 to take
There is currently no established medical or regulatory-approved human dosing protocol for BPC-157. Published experiments have used different routes, concentrations and periods of treatment, depending on the animal model and the tissue investigated.
Therefore, a laboratory research protocol should be built on:
- The model under experimental study
- The route of administration allowed for by the study
- Subject weight or cell culture concentration
- The biological pathway or tissue being investigated
- Suitable control and comparison groups
- Ethical and institutional approval
- Predefined study and monitoring endpoints
Here is a typical research protocol for BPC 157
Dosage Chart
| Tier | Dosage | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | 200mcg | Once Daily | |
| Weeks 3-4 | 400mcg | Once Daily | |
| Weeks 5-8+ | 600mcg | Once Daily |
BPC-157 peptide benefits
BPC-157 is under investigation for possible effects such as the following:
Tendon and ligament repair
Muscle recuperation
Fibroblast motility and activity
Collagen production and arrangement
Blood vessel and angiogenic signalling
Protection of gastrointestinal mucosa
Wound repair
Inflammatory signalling
Modulation of the nitric oxide pathway
bone-to-tendon healing
Recovery after experimental tissue injury
BPC-157 has been shown to improve healing of transected Achilles tendons and surgically injured ligaments in rodent studies. Laboratory work has also reported increased tendon cell outgrowth and migration. These are experimental results, not clinically proven human benefits.
What does BPC 157 do?
BPC-157 is being studied for its potential effects on various biological pathways involved in tissue protection and repair. The exact mechanism of action is not fully known. Most of the data supporting its use are from laboratory and animal studies and not from controlled clinical studies in humans.
Studies indicate that BPC-157 may affect the activity and motility of fibroblasts, the cells that produce collagen and rebuild connective tissue. In laboratory tendon models, BPC-157 increased fibroblast migration, spreading and survival during stress. The researchers associated these effects with activation of the FAK–paxillin signalling pathway, which is important in cell attachment and movement.
Other potential effects of BPC-157 include:
- Formation and organisation of collagen
- Tendon cell growth and migration
- Vasculogenesis
- Nitric oxide signalling
- Gastrointestinal tract mucosal protection
- Inflammatory response
- Blood flow to injured tissue
One of the mechanisms proposed is through the VEGFR2-Akt-eNOS pathway. Experimental studies have shown that BPC-157 increased VEGFR2 expression and activation, and promoted endothelial tube formation and blood-flow recovery in a rat model of hind-limb ischaemia. These findings indicate a potential effect on angiogenesis (new blood vessel formation) but this has not been shown to be beneficial in humans.
Improved collagen organisation, biomechanical strength and functional recovery following experimentally induced Achilles-tendon injury have also been demonstrated in animal studies. These are promising findings, but we cannot assume they will have the same effect in humans.
In brief, BPC-157 is believed to act through a mixture of cellular migration, vascular signalling, nitric-oxide regulation and tissue-protective mechanisms. However, the exact pharmacology, effective human dose and long-term safety profile are unknown.
BPC 157 Side Effects
The adverse effect profile of BPC-157 in humans has not been sufficiently established. Lack of adverse effects in small or preclinical studies should not be considered as evidence for safety.
Some potential concerns include:
- Pain, redness or swelling at the injection site
- Contamination or infection from unsterile handling
- Immune response / allergy
- Headache, nausea or giddiness
- Side effects on blood vessel formation
- Unpredictable interactions with the drugs or with other peptides
- Uncertain effect on blood pressure and nitric oxide signalling
- Unknown long term effects.
- peptide impurities, degradation products or wrong concentration
Lifestyle Factors
The way you live your life and the rehab you do can make a huge difference to your recovery from tendon, ligament, muscle and gastrointestinal injuries. These factors should be taken into account when assessing any research that examines BPC-157, as they can influence the outcomes of studies and make it challenging to determine which changes are attributable to the peptide itself.
Proper Rehabilitation
Progressive rehabilitation is one of the most important factors in recovery from musculoskeletal injury. Too long a period of complete rest can diminish strength and tissue capacity, while too early a resumption of heavy activity can exacerbate an injury.
A structured programme could include:
- Loading of affected tissue in gradual manner
- Range of Motion Work
- Progressive resistance exercise
- Sport-specific/activity-specific rehabilitation
- Tracking pain and function over time
Rehabilitation should be appropriate to the type and severity of the injury and guided by a qualified health care or rehabilitation professional where necessary.
Protein & Nutrition
Normal tissue maintenance and repair are supported by adequate caloric and protein intake. Low energy intake can hinder recovery, especially in combination with heavy training or physical work.
A sound diet should supply sufficient:
- Protein Fibre
- Vitamin C (ascorbic acid)
- Zinc.
- Copper.
- Iron
- EFAs essential fatty acids
- Carbohydrates for Training and Rehabilitation
Supplements are no substitute for a poor overall diet and individual vitamins or minerals in excess can be harmful.
Rest.
Sleep aids normal immune function, hormonal regulation, and recovery from physical activity. Training performance may be impaired, pain sensitivity increased and rehabilitation interfered with by poor or inconsistent sleep.
A regular sleep schedule and sufficient recovery time between hard training sessions can help provide consistent research or rehab conditions.
Training Volume
Further overloading of an injured structure could retard recovery irrespective of the compound under investigation. Therefore training volume, intensity and frequency should be adapted to symptoms and function.
Researchers need to record any changes in levels of exercise and activity, otherwise improvements may be wrongly attributed to the intervention.
Alcohol and Tobacco
Smoking can impair blood flow and has been associated with poorer healing of tissue. Heavy alcohol consumption can also negatively affect sleep, nutrition, inflammation and recovery behaviours.
Reducing these factors may help support general health and more reliable study conditions.
Hydration and Your General Health
Things that affect recovery are hydration, circulation, metabolic health and pre-existing medical conditions. Conditions such as diabetes, vascular disease, and chronic inflammatory disorders can interfere with normal tissue-healing processes.
BPC-157 should not be considered a replacement for diagnosis, rehabilitation, proper nutrition, or medical treatment.
Scientific References
- Chang CH, et al. — Tendon Fibroblast Migration
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. The study reported increased tendon-fibroblast migration, spreading and survival, potentially involving activation of the FAK–paxillin pathway.
View the study on PubMed - Staresinic M, et al. — Achilles-Tendon Healing
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth. Journal of Orthopaedic Research. 2003;21(6):976–983. In a rat Achilles-tendon model, researchers reported improvements in biomechanical strength, collagen formation, functional measurements and tendon integrity.
View the study on PubMed - Hsieh MJ, et al. — VEGFR2 and Angiogenic Signalling
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. The study examined endothelial-cell activity and a rat model of hind-limb ischaemia. BPC-157 was associated with VEGFR2 activation, endothelial tube formation and improved blood-flow recovery.
View the study on PubMed - Chang CH, et al. — Tendon Cell Activity
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival and cell migration. This laboratory study provides mechanistic evidence relating to cell migration, cytoskeletal changes and FAK–paxillin signalling.
View the study on PubMed - Gwyer D, Wragg NM, Wilson SL — Musculoskeletal Evidence Review
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft-tissue healing. Cell and Tissue Research. 2019;377(2):153–159. This review examined research involving tendon, ligament and skeletal-muscle healing. The authors noted that the majority of evidence came from small rodent models and that efficacy had not been confirmed in humans.
View the study on PubMed - Sikiric P, et al. — Angiogenesis and Gastrointestinal Protection
The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation-tissue formation. This animal study investigated angiogenesis, granulation-tissue formation, gastrointestinal protection and interactions with the nitric-oxide system.
View the study on PubMed - US Food and Drug Administration — BPC-157 Safety Position
Certain bulk drug substances for use in compounding that may present significant safety risks. The FDA states that compounded BPC-157 may carry risks relating to immunogenicity, peptide impurities and active-ingredient characterisation. It also notes that there is insufficient safety information to determine whether BPC-157 may cause harm when administered to humans.
View the FDA safety information
BPC 157 FAQ's
What Does BPC-157 Do?
BPC-157 is an experimental peptide that is being studied for its possible effects on tissue repair pathways, fibroblast activity, collagen organisation, angiogenic signalling and gastrointestinal protection.
Animal studies have shown promising results in tendon, ligament, muscle and digestive tissue injury. But BPC-157 has not been shown to heal injuries or treat medical conditions in humans.
How Do You Inject BPC-157?
There is no approved or clinically validated BPC-157 injection method in humans. Self injection is not risk free Risks of infection, contamination, wrong concentration, harm to tissues and immune reactions. It’s not a licenced injectable medication.
The research community, however, prefers subcutaneous (under the skin) for most injuries. Deep muscle injuries can be managed with intramuscular.
How Long Does BPC-157 Take to Work?
It is contingent upon the condition being treated, but BPC-157 works in a short time. Generally expect the first effects for acute injuries and inflammatory conditions in 3-7 days. Healing usually occurs significantly at 2-4 weeks with full recovery in 4-12 weeks depending on the condition and severity. * Gut problems usually resolve in 1-2 weeks, but tendons and ligaments take longer because of poor blood supply. Noting that these time frames are based on animal studies and may not directly predict human response.
How Do You Take BPC-157?
BPC-157 has been studied in preclinical studies given orally, topically and by injection. But there is no approved route for general human therapy, no standard protocol for human administration.
What Is BPC-157 Used For?
In experimental research, BPC-157 is used to investigate biological pathways related to the following:
Tendon and ligament repair
Muscle trauma
Wound repair
Gastroprotection
Blood vessel control
Inflammatory reactions
Fibroblast & Collagen Stimulation
Bone-to-tendon healing
Where Do You Inject BPC-157?
BPC-157 is usually administered subcutaneously in the area of injury or in the abdominal fat for systemic delivery.
Sites of injection
Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, rotator cuff) subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, or rotator cuff), subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs. Local Injection Near Injury: For musculoskeletal injury (knee, shoulder, Achilles tendon, or rotator cuff), subcutaneously within 1–3 cm of the injured tissue to obtain a high local concentration during the first 15–30 min before systemic diffusion occurs.
Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues. Examples: Fatty tissue surrounding the knee for knee injuries. Tricep area for shoulder or elbow injuries. Outer thigh for quad or hamstring issues.
Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen): Systemic Injection (Fat in Abdomen):
For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption . For deep injuries (hip joint, spinal disc) or gut related problems (IBS, gastric ulcers) inject into the lower abdominal fat for systemic absorption .
The abdomen is also a common spot for general use if you are not targeting a specific injury. The abdomen is also a common spot for general use if you are not targeting a specific injury. The abdomen is also a common spot for general use if you are not targeting a specific injury. The abdomen is also a common spot for general use if you are not targeting a specific injury. Alternate between left and right side to prevent irritation Alternate between left and right side to prevent irritation Alternate between left and right side to prevent irritation Alternate between left and right side to prevent irritation
Other Sites Optional: Other Sites Optional: Other Sites
Upper hip (above waistband) for site rotation or for patients with limited abdominal fat. Upper hip (above waistband) for site rotation or for patients with limited abdominal fat. Upper hip (above waistband) for site rotation or for patients with limited abdominal fat.
Easy access and comfort to the outer thigh's middle third
Is BPC-157 Legal?
It depends on the country, how the product is presented, and the intended use of the product.
BPC-157 is not an approved medicine in the UK. If a product is advertised or presented as treating, preventing or repairing a human medical condition, it may be caught by medicines legislation and require appropriate authorisation from the MHRA. Something labelled “for research use only” does not mean that regulatory obligations go away if the broader presentation suggests intended human use.
BPC-157 is also banned at all times for athletes governed by the rules of the World Anti-Doping Agency. It is included in the S0 Non-Approved Substances category of the 2026 Prohibited List.
BPC-157 Peptide: Where Can You Buy It?
We at Kensington Labs are proud to offer Premium research grade BPC 157, laboratory tested by a third party for purity and strength.
How Much Bacteriostatic Water Should Be Mixed With 5mg of BPC-157?
The amount depends on the concentration the laboratory protocol requires. You will not increase the amount of BPC-157 in the vial; rather, you dilute the solution more by adding more water.
Some common concentration calculations are:
5,000mcg/ml or 50mcg in 0.01ml, 1ml added
Added 2ml 2,500mcg/ml or 25mcg per 0.01ml
3 ml added: ~1,667 mcg/ml or 16.7 mcg/0.01 ml
How Long Does BPC-157 Stay in Your System?
BPC-157 clears from the bloodstream within hours, but its biological effects can last for days to weeks.
